Viscosupplementation Market – Global Forecast 2025-2033

Market Overview

The global viscosupplementation market is projected to reach US$ 10.16 Billion by 2033, up from US$ 4.66 Billion in 2024, growing at a CAGR of 9.02% during 2025 to 2033. This surge is fueled by the increasing prevalence of osteoarthritis, rising geriatric population, and growing demand for non-invasive joint pain treatments.

Viscosupplementation, which involves injecting hyaluronic acid into joints (mainly the knee), helps improve joint lubrication, reduce pain, and delay degeneration—making it a preferred option over surgery.

Related Report

Assisted Reproductive Technology Market

Weight Loss Market 

Bariatric Surgery Devices Market

Market Segmentation

By Injection Type

• Single Injection
• Three Injections
• Five Injections
  Single-injection products are witnessing rising demand due to patient convenience, lower clinic visits, and innovation in long-acting HA formulations.

By Application

• Knee (Dominant Segment)
• Hip
• Hand/Wrist
• Ankle/Foot
• Others
  Knee osteoarthritis remains the largest application area due to aging-related cartilage wear, particularly in elderly populations.

By End User

• Hospitals
• Orthopedic Clinics/Ambulatory Surgical Centers
  Orthopedic clinics and ambulatory centers are gaining traction due to the increasing shift toward outpatient procedures and minimally invasive care.

Market Drivers

• Rising Osteoarthritis Cases: The aging population is a key driver, with millions suffering from joint degeneration annually.
• Minimally Invasive Preference: Patients and providers prefer injectable solutions over surgical interventions.
• Advancements in HA Formulations: Newer HA products offer long-lasting relief and require fewer injections, improving treatment adoption.

Market Challenges

• High Treatment Costs: Expensive procedures with limited insurance coverage may deter patients.
• Lack of Awareness: Many patients and even healthcare providers remain unaware of viscosupplementation’s benefits.

Regional Insights

United States

• One of the most advanced markets with strong demand for non-surgical OA treatment.
• Supported by R&D investments, growing insurance access, and innovative products like Anika Therapeutics’ Cingal, which showed positive Phase III results in 2022.

France

• Favorable healthcare system, aging population, and high awareness support steady market expansion.
• Rising adoption of hyaluronic acid therapies and minimally invasive procedures contributes to growth.

China

• Growth driven by demographic shifts, rising OA cases, and healthcare modernization.
• Interest in avoiding costly surgeries is boosting demand for injectable therapies.

Saudi Arabia

• Increasing elderly population and a shift towards non-invasive joint care support market growth.
• Government healthcare reforms and high-end infrastructure help promote adoption of viscosupplementation.

Key Companies

• Anika Therapeutics Inc.
• Zimmer Biomet
• Smith & Nephew PLC
• Sanofi
• F. Hoffmann-La Roche Ltd.
• Chugai Pharmaceutical Co.
• Lifecore Biomedical
• LG Life Sciences Ltd.
• Bioventus Inc. – Recently partnered with Aetna™ Medicare Advantage (Dec 2023)

Key Statistics

Future Outlook

With continuous advancements in HA formulation, increasing OA prevalence, and the shift toward outpatient & non-invasive treatments, the viscosupplementation market is set to grow robustly across the globe.